October 30, 2018
Shionogi enjoyed all-time highs in its April-September profits, but a generic onslaught for its cholesterol fighter Crestor (rosuvastatin) continued to eat into its revenue in Japan, with its topline skidding 2.3% to 168 billion yen, the company said on October...read more